Epilepsy Foundation Establishes a Patient Research Ambassador Program to Inform Clinical Research
The Epilepsy Foundation of America established a research ambassador program to equip individuals with epilepsy and their caregivers with the knowledge and skills needed to actively contribute to clinical research and product development. Through structured training and ongoing collaboration with industry, funders, and researchers, these ambassadors participate in activities to ensure that studies and technologies reflect real-world needs.
Quick Facts Organization name: Epilepsy Foundation of America |
Product Type(s)
medical device:
- implantable device
- home-use device
- therapeutic device
- aesthetic device
digital health technology:
- health and wellness
- patient monitoring (sensors, etc.)
- care support
- digital diagnostic
- digital therapeutic
- non-health system software
Product Medical Specialty Area(s)
- neurology
Stakeholders Involved in Patient Engagement Efforts
- medtech company: internal discovery/research and development (R&D) teams
- medtech company: internal clinical affairs/R&D teams
- medtech company: internal medical affairs teams
- medtech company: internal marketing teams
- patients and caregivers, patient organizations
- investors (government, philanthropic, and private)
- providers (clinicians, hospital/health system administrators)
Methods and Sources of Patient Input
- patient advisory boards
- patient advocacy organizations
- interviews/focus groups/surveys
- public comment/testimony
- advisory committee participation (including Data and Safety Monitoring Board)
- patient-generated health data
- patient-led registries
- patient-focused drug development Voice of the Patient reports
- patient-driven research agendas and investments
- patient preference information/studies
- real-world data/evidence
- social media/online listening
Purpose of Patient Engagement
To foster trust and improved communication between these communities, the Epilepsy Foundation of America launched a Research Ambassador program. Its mission is to empower collaboration between individuals from the epilepsy community, grant organizations, government funders, academic researchers, and therapy developers to foster inclusive, innovative epilepsy research that will lead to meaningful improvements in symptoms and quality of life.
This program creates a system for consistent and collaborative engagement between the R&D enterprise and the epilepsy community. The intent is to provide education to people with lived experience of epilepsy (either personal or caregivers/family members) so they can engage with the research community. It also includes education on the purpose of research, components of clinical trials, and the regulatory process. Medtech and pharmaceutical companies can partner with the Epilepsy Foundation to coordinate outreach with the research ambassadors to host focus groups or surveys that will facilitate conversation and generate insights to inform clinical trials, protocols, product development, and clinical research. Ambassadors can reach back out to their communities to encourage trial participation. The Epilepsy Foundation brings these groups together in its research initiatives to encourage multidisciplinary engagement.
Description of Patient Engagement Activities
Pharmaceutical companies and academic investigators search for input from people with lived experience to inform and improve their clinical trials. However, epilepsy community members have indicated a clear desire for more background knowledge before volunteering. The Research Ambassadors program was created to empower the community’s voice in research, so treatments address the real-life challenges faced by individuals living with epilepsy. Ambassadors are selected through a competitive process.
The Foundation shares the application with its regional affiliates, professional advisory boards, patient organizations, research ambassadors, and on social media. Individuals living with epilepsy, caregivers for someone with epilepsy, or others who are uniquely positioned to support the epilepsy community can apply for the program. A selection committee reviews each application, prioritizing a diverse set of backgrounds, perspectives, and experiences. Selected candidates participate in a comprehensive curriculum that includes prerecorded lectures and a full-day, immersive boot camp on the foundations of research, the drug and device development process, and clinical trial recruitment.
Medtech and therapeutic companies are also invited to the boot camp to encourage multidisciplinary collaboration. Once ambassadors complete the program, they are invited to Epilepsy Foundation activities, such as the Research Roundtable for Epilepsy, or focus groups for industry therapy developers.
Impact of Patient Engagement
Since the program began in 2025, it has trained nearly 40 Research Ambassadors, with 19 participating in biotech company focus groups, two ambassadors joining the Rally for Medical Research, two Ambassadors participating in a panel at the American Epilepsy Society annual meeting, and one ambassador sitting on the National Action Plan for Epilepsy Committee. The Ambassadors’ feedback and experiences have been incorporated into publications, programming, clinical trial design, and symptom severity scales. When the Ambassadors serve as expert panelists at events such as the American Epilepsy Society annual meeting or focus groups, they share their experience and tangible insights. Their experiences can provide actionable ways for industry therapy developers to integrate new insights or pivot their processes to reflect community needs. Ambassadors have also brought their experience with the program back to their communities. Some ambassadors have hosted webinar sessions to share their knowledge of clinical trials with their networks, and others have spoken about clinical research and their experiences at state seizure conferences.
Lessons Learned
By participating in program activities, ambassadors share their experiences with clinical trials, medications they have tried, and clinical care systems. This can range from the challenges of accessing physicians specializing in the treatment of epilepsy to the feasibility of taking medications on an empty stomach. These experiences provide valuable insights to therapy developers as they develop therapeutics, clinical trials, and diagnostic tools. It also ensures treatments and devices are focused on the real-life challenges of those living with epilepsy. Additionally, ambassadors have had the opportunity to comment on inclusion/exclusion criteria, trial designs, and ethical issues of remote consent for a trial sponsored by the National Institutes of Health.